1 / 1

ENDEAVOR II

ENDEAVOR II. Target vessel failure at 9 months: 7.9% for Endeavor vs. 15.1% for Driver Target lesion revascularization at 9 months: 4.6% vs. 11.8% (p = 0.0001), respectively Death: 1.2% vs. 0.5% (p = 0.34), respectively Stent thrombosis: 0.5% vs. 1.2%, respectively.

hamal
Download Presentation

ENDEAVOR II

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ENDEAVOR II Target vessel failure at 9 months: 7.9% for Endeavor vs. 15.1% for Driver Target lesion revascularization at 9 months: 4.6% vs. 11.8% (p = 0.0001), respectively Death: 1.2% vs. 0.5% (p = 0.34), respectively Stent thrombosis: 0.5% vs. 1.2%, respectively Trial design: Stable patients with native coronary disease were randomized to DES (n = 598) versus BMS (n = 599). Primary outcome was target vessel failure at 9 months. Results (p = 0.0001) 15.1 % 7.9 (p = 0.22) Conclusions • Among stable patients undergoing PCI for a single de novo lesion, the use of the Endeavor drug-eluting stent was beneficial. • This stent reduced target vessel failure and target lesion revascularization compared with a Driver bare-metal stent. 1.2 0.5 Target vessel failure Stent thrombosis DES BMS Fajadet J, et al. Circulation 2006;114:798-806

More Related